Laekna (HKSE:02105) Cash-to-Debt : 10.37 (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Laekna Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Laekna's cash to debt ratio for the quarter that ended in Jun. 2024 was 10.37.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Laekna could pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for Laekna's Cash-to-Debt or its related term are showing as below:

HKSE:02105' s Cash-to-Debt Range Over the Past 10 Years
Min: 10.37 Med: 11.42 Max: 19.11
Current: 10.37

During the past 3 years, Laekna's highest Cash to Debt Ratio was 19.11. The lowest was 10.37. And the median was 11.42.

HKSE:02105's Cash-to-Debt is ranked better than
55.88% of 1487 companies
in the Biotechnology industry
Industry Median: 6.4 vs HKSE:02105: 10.37

Laekna Cash-to-Debt Historical Data

The historical data trend for Laekna's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Laekna Cash-to-Debt Chart

Laekna Annual Data

Trend

Dec21

Dec22

Dec23

Cash-to-Debt

10.65

11.42

13.82

Laekna Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash-to-Debt	Get a 7-Day Free Trial			N/A	11.42	19.11	13.82	10.37

Competitive Comparison of Laekna's Cash-to-Debt

For the Biotechnology subindustry, Laekna's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laekna's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laekna's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Laekna's Cash-to-Debt falls into.

Laekna Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Laekna's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	851.983	/	(56.129	+	5.544)
	=	13.81

Laekna's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	706.537	/	(63.618	+	4.51)
	=	10.37

Laekna (HKSE:02105) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Laekna Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Laekna's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Laekna Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

4U4:Germany

Address

No. 3-2-467, 5 Xingbin Road (Lin Li Center), Sino-Italy Ningbo Ecological Park, Zhejiang Province, Yuyao, CHN, 201203

Website

https://www.laekna.com

Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.

Executives

Gp Healthcare Capital, Inc.	2101 Beneficial owner
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Liu Zeng	2201 Interest of corporation controlled by you
Zhong Yi Ning Bo Sheng Tai Yuan Kong Gu Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Yao Shang Yan Chuang Si Mu Ji Jin Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Yao Shang Yan Chuang Shou Ren Gu Quan Tou Zi You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Yan Chuang Hou De Tou Zi Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Bei Jing Chun Lin Xin Xi Zi Xun Zhong Xin You Xian He Huo	2201 Interest of corporation controlled by you
Bei Jing An Long Chuang Ye Tou Zi Ji Jin You Xian He Huo	2201 Interest of corporation controlled by you
Liu Ying	2201 Interest of corporation controlled by you
Guo Tou Zhao Shang Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin Er Qi You Xian He Huo	2101 Beneficial owner
Yu Yao Yang Ming Gu Quan Tou Zi Ji Jin You Xian Gong Si	2101 Beneficial owner
Futu Trustee Limited	2301 Trustee

Laekna Headlines

No Headlines